Drug therapy problems among pediatric patients with infectious diseases admitted to Debre Birhan Hakim Gizaw teaching hospital in Ethiopia Authors: Sisay Sitotaw Anberbr, Yonas Demissie Bahru, Melese Yikan, Jenber Workye Sahlie, Kalab Yigermal Gete, Dessale Abate Beyene, Abate Wondesen Tsige Published: 2026 ABSTRACT AbstractDrug therapy problem (DTP) is any event involving drug therapy that interferes with a patient’s desired clinical outcome. It is associated with morbidity, mortality, increased hospital stays, and reduced quality of life. Moreover, pediatric patients are quite susceptible to DTP. To determine drug therapy problems and their contributing factors among pediatric patients with infectious diseases admitted at the pediatric ward of Debre Birhan Hakim Gizaw Teaching Hospital (DBHGTH), Ethiopia. A hospital-based prospective follow-up study was conducted at DBHGTH from March 1 to August 31, 2024. To ensure that the sample was representative, a systematic random sampling technique was employed to select participants. Data was collected from interviewing patients’ parents/caregivers, older children, and reviews of patients’ medical records using prepared standard data abstraction tools and structured questionnaires. Data was analysed by SPSS version 27.0. Binary logistic regression analysis was used. Statistical significance was determined at a 95% CI, with a p-value < 0.05 considered statistically significant. Of the total 163 participants, 70 (42.94%) [95% CI (35.52–50.90%)] of them had at least one DTP during their hospital stay. A total of 201 DTPs were identified among 70 patients. Antibiotics were the most frequently prescribed drug class, with a mean of 1.73 antibiotics per child. Needs additional drug therapy (27.86%) and patient noncompliance (18.90%) were the most predominant encountered DTPs. The most important interventions made were the addition of drugs (28.29%), followed by patient education/counseling/adherence (24.30%). Patients living in rural area [AOR: 4.58, 95%CI: 1.94–10.81, p < 0.001]; patients using traditional herbal [AOR: 4.66, 95%CI: 1.28–16.97, p = 0.020]; patients with the prolonged hospital stay (> 10 days) [AOR: 6.18, 95%CI: 1.95–19.56, p = 0.002]; patients with high number of medications (≥ 5) [AOR: 3.91, 95%CI: 1.33–11.48, p = 0.013]; and patients with high number of comorbidity (> 1) [AOR: 4.27, 95% CI: 1.60–11.37, p = 0,004] were the predictors of the occurrence of DTPs. The prevalence of DTPs in the pediatric ward was moderate. It implies a substantial burden requiring attention. It was found that the majority of the problems were related to indication, whereas the need for additional drugs was the predominant DTP. Antibiotics were the commonly prescribed classes of drugs involved in DTPs.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-58116-7.Keywords: Drug therapy problems, Paediatric patients, Debre Birhan University, EthiopiaSubject terms: Diseases, Health care, Medical research, Risk factors Introduction Pediatric patients are a special population of those younger than 18 years old. They differ from adults and within their age groups in body surface area, weight, and organ function development, which affect the efficacy and safety of pharmacotherapy1,2. The immunity of the children is not well developed. This makes them vulnerable to serious and potentially lethal infectious diseases3. The World Health Organization (WHO) reported that infectious diseases, including acute respiratory infections, diarrhoeal diseases, and malaria, remain major causes of post-neonatal and under-five mortality globally. In 2023, about 4.8 million children died before the age of five worldwide, with pneumonia remaining the leading infectious killer of under-five children, causing more than 700,000 deaths annually, while diarrhoea and malaria also contributed substantially to preventable childhood deaths, particularly in sub-Saharan Africa4–6. Populations in low- and middle-income countries (LMICs), especially in sub-Saharan Africa and Southeast Asia, are disproportionately burdened by preventable infectious diseases, largely because of inadequate access to clean water and sanitation facilities, widespread malnutrition, and limited healthcare access. According to the WHO, the majority of deaths associated with unsafe water, sanitation, and hygiene occur in the African and South-East Asia regions, with low- and lower-middle-income countries accounting for nearly 89% of the global burden7,8. In developing countries, infectious diseases remain among the most common medical problems affecting the pediatric population. Recent studies conducted in sub-Saharan African countries, including Ethiopia and Nigeria, as well as North African countries such as Egypt, have shown that infectious diseases continue to account for a substantial proportion of pediatric hospital admissions and outpatient visits9–11. Pneumonia, sepsis, meningitis, malaria, acute gastroenteritis, upper respiratory tract infections, and intestinal parasitic infections remain the most frequently reported infectious diseases among children in these settings. Consequently, antibiotics such as ampicillin, gentamicin, ceftriaxone, and crystalline penicillin are commonly prescribed for the treatment of these infections12–14. However, the increasing burden of antimicrobial resistance among pediatric pathogens has become an important public health concern in low- and middle-income countries. The mainstay of treatment for infectious diseases is the use of antibiotics. However, its irrational selection and application will result in problems like drug resistance, incorrect dosage, incorrect frequency, incorrect duration, adverse drug events, and drug interactions. Therefore, healthcare professionals should exercise great caution while prescribing, distributing, and administering antibiotics to pediatric patients15,16. A drug therapy problem (DTP) is defined as an undesirable event involving drug therapy that actually or potentially interferes with desired health outcomes and requires professional judgment to resolve it17. It can originate in any process of medication use (prescribing, transcribing and verifying, dispensing, administering, monitoring, and reporting18. Drug therapy problems are classified into seven7 categories, which are unnecessary drug therapy, needs additional drug therapy, ineffective drug, dosage too low, adverse drug reaction (ADR), dosage too high, and non-compliance. The first two categories of DTPs are associated with the indication. The third and fourth categories of DTPs are associated with effectiveness. The fifth and sixth categories of DTPs are associated with safety. The seventh category deals with patient-related problem (compliance)19,20. Different factors contribute to the occurrence of DTPs. These include: missing information, poor patient knowledge of the drug use, polypharmacy, administration of drugs with a narrow therapeutic range, co-morbidity, and hepatic and renal impairment21. The pediatric population is at high risk for DTPs. This may be due to differences in drug Pharmacodynamics, Pharmacokinetics, and clinical heterogeneity such as weight, body surface area, age, and organ function development, which are the determinants of dose and drug selection. In addition to these, there are a limited number of studies available concerning the safety and effectiveness of the drugs in this specific group of populations22. The differences in drug pharmacokinetics and pharmacodynamics observed in children influence the choice of the drug, dose, dosage form, and dosing interval23. Many medicines needed for pediatric patients are not available in appropriate dosage forms; thus, the dosage forms of drugs marketed for adults may require modification for use in infants and children, necessitating assurance of potency and safety of drug use. The pediatric medication-use process is complex and error-prone because of the multiple steps required in calculating, verifying, preparing, and administering doses. This, in turn, indicated epidemiologic characteristics of DTPs differ between adults and children24. Therefore, an updated investigation to know and decrease the magnitude of DTPs among these populations is required in the study setting. Consequently, this study aimed to determine drug therapy problems and their contributing factors among pediatric patients with infectious diseases admitted at the pediatric ward of Debre Birhan Hakim Gizaw Teaching Hospital (DBHGTH), Ethiopia. Methods and materials Study design, area, and period A prospective follow-up study was conducted from March 1 to August 31, 2024, within the pediatric ward of DBHGTH, which is affiliated with Debre Birhan University. The hospital is situated in Debre Birhan, a town located approximately 130 km northeast of Addis Ababa, the capital city of Ethiopia, in the North Shewa zone of the Amhara region. According to data from the Debre Birhan town administration, the town encompasses an area of 14.9 km2 and has an estimated population of 209,010 residents. DBHGTH is a major healthcare facility in the region, comprising four main inpatient wards: Medical, Surgical, Pediatric, and Gynaecology and Obstetrics. In addition to these wards, the hospital provides a range of outpatient services through its four outpatient departments. The facility is equipped with multiple pharmacies, including an adult emergency pharmacy, an outpatient department pharmacy, and an inpatient department pharmacy, ensuring the availability of medications for both acute and chronic care needs. Furthermore, the hospital features a dedicated Emergency Room to manage urgent and life-threatening conditions. This comprehensive infrastructure supports the delivery of a wide spectrum of medical services to the local population and surrounding communities. Source population All patients admitted to the DBHGTH pediatrics ward were taken as the source population. Study population All pediatric patients with infectious diseases admitted to the pediatric ward of DBHGTH during the study period and who fulfilled the inclusion criteria were included. Sample size determination The number of patients needed for the study was calculated using a formula that considers a 95% confidence level, a 5% margin of error, and the prevalence of DTP in Zewditu Hospital (31.57%)25, resulting in the following: Where: Z = 1.96, the standard score (critical value) corresponding to a 95% CI. Z = 1.96, the standard score (critical value) corresponding to a 95% CI. p = 0.3157 represents the estimated percentage of DTP. p = 0.3157 represents the estimated percentage of DTP. d = 5%, the proportion of sampling error. d = 5%, the proportion of sampling error. n = sample size. n = sample size. The expected number of source population in the study period (N), based on the average number of patients admitted to the pediatric ward who had received pediatric services within the study period, within a total of six months, was 311 patients (obtained from electronic medical records). Then we can use the correction formula if it is < 10,000. Adjusted = = 161 Patients. Where n = total sample size to be calculated, N = total population for six months, and nf = minimum sample size in the pediatric ward. By adding a 10% non-response rate, the final sample size was nfinal = 161 + 10%=161 + 16=177 individuals. The total final sample size was n = 177, but in the current study, 163 pediatric patients were involved by using a systematic random sampling technique with a response rate of 92.09% (163/177); fourteen study participants (seven parents, three guardians, and four older children) were withdrawn because of unwillingness to take part in the study. To select participants during the study period, a systematic random sampling technique was employed. First, the sampling interval (K) was determined by dividing the total number of pediatric patients admitted during the study period (311) by the calculated sample size (163), yielding a value of approximately 1.9, which was rounded to 2. Next, the starting point was selected randomly from the first two patients. Each day, a patient list was prepared, and systematic sampling was applied by selecting every second patient until the required sample size was achieved. Participants were then interviewed, and relevant data were concurrently collected from their medical charts. Inclusion and exclusion criteria Inclusion criteria Pediatric patients (age < 18 years) admitted to the pediatric wards of DBHGTH and stayed for more than 24 h, diagnosed with at least one infectious disease, and received at least one medication, and older children and pediatric patients whose parent/guardian signed the written informed consent were included in the study. Exclusion criteria Pediatric hospitalized patients who were readmitted, patients who stayed less than 24 h, pediatric patients who were admitted to the intensive care unit (ICU), and those whose parents or legal guardians did not provide written informed consent were excluded from the study. Data collection method Participants were selected daily using a systematic random sampling technique from pediatric patients admitted to the ward during the study period. At admission, interviews were conducted with parents/caregivers and, when appropriate, older children using a structured questionnaire to obtain information on sociodemographic characteristics, place of residence, past medical history, previous medication use, and use of traditional or herbal medicines. Following the interviews, relevant clinical information, including comorbidities, prescribed medications, disease severity, level of consciousness, polypharmacy status, laboratory findings, length of hospital stay, and anthropometric measurements, was extracted from patients’ electronic medical records using a standardized data abstraction tool. Patients were followed prospectively throughout hospitalization until discharge. Drug therapy problems (DTPs) were assessed daily during hospitalization using a modified Cipolle’s DTP classification scheme (19) by evaluating the appropriateness of therapy in terms of indication, effectiveness, dosage, safety, and adherence. Clinical pharmacists discussed identified DTPs with physicians and provided patient or caregiver education and counselling on medication adherence and other medication-related issues whenever necessary during the course of treatment. Study variables Dependent variables Drug therapy problems (DTPs) (Yes/No). Independent variables Age, sex, weight, place of residence, disease and drug-related variables, number of drugs used, comorbidity, use of traditional herbal medicine, number of disease conditions, class of drug prescribed, patient-related factors, length of hospital stay, and polypharmacy. Operational definition definitions Pediatric Patient: A patient whose age ranges from birth up to the age of 18 during the study period26. Infectious disease: A disease caused by pathogenic micro-organisms such as bacteria, fungi, Viruses, protozoa, worms, and parasites27. Comorbidity disease: A medical condition diagnosed other than infectious diseases and whose cause is not by microorganisms28. Polypharmacy is defined as the concomitant use of five or more prescription medications recorded in the patient’s medical chart during hospitalization29. Drug therapy problem (DTPs) is defined as an undesirable event involving drug therapy that actually or potentially interferes with desired health outcomes and requires professional judgment to resolve it17,30,31. The DTPs evaluation tool was developed based on Cipolle’s and Strand’s drug therapy problem classification system, a widely accepted patient-centred standard used in clinical pharmacy practice. The identified DTPs were classified and defined as follows17: Unnecessary drug therapy is a DTP that occurs when there is no valid medical indication for the drug at the time, multiple drug products are used when only single-drug therapy is appropriate, or the condition is best treated with non-drug therapy32,33. Additional drug therapy is a DTP that occurs when there is a medical condition needing new drug therapy, preventive therapy is needed to reduce the risk of developing a new condition, or a medical condition requires combination therapy for better efficacy33,34. Additional drug therapy is a DTP that occurs when there is a medical condition needing new drug therapy, preventive therapy is needed to reduce the risk of developing a new condition, or a medical condition requires combination therapy for better efficacy33,34. Ineffective drug therapy is a DTP where the drug is not the most effective for the medical problem, the drug product is not effective for the medical condition, the condition is refractory to the drug product being used, or the dosage form is inappropriate33,35. Ineffective drug therapy is a DTP where the drug is not the most effective for the medical problem, the drug product is not effective for the medical condition, the condition is refractory to the drug product being used, or the dosage form is inappropriate33,35. Dosage too low is a DTP that occurs when the dose is too low to produce the desired outcome, the dosage interval is too infrequent, a drug interaction reduces the amount of active drug available, or the duration of therapy is too short33,35. Dosage too low is a DTP that occurs when the dose is too low to produce the desired outcome, the dosage interval is too infrequent, a drug interaction reduces the amount of active drug available, or the duration of therapy is too short33,35. Dosage too high is a DTP where the dose is too high, the dosing frequency is too short, the duration of therapy is too long for the patient, a drug interaction causes a toxic reaction to the drug product, or the dose was administered too rapidly33,36. Dosage too high is a DTP where the dose is too high, the dosing frequency is too short, the duration of therapy is too long for the patient, a drug interaction causes a toxic reaction to the drug product, or the dose was administered too rapidly33,36. Adverse drug reaction is a DTP where the drug product causes an undesirable reaction that is not dose-related, a safer drug is needed because of patient risk factors, a drug interaction causes an undesirable reaction that is not dose-related, or the regimen was administered or changed too rapidly33,37. Adverse drug reaction is a DTP where the drug product causes an undesirable reaction that is not dose-related, a safer drug is needed because of patient risk factors, a drug interaction causes an undesirable reaction that is not dose-related, or the regimen was administered or changed too rapidly33,37. Non-compliance: The patient is considered to be noncompliant with the drug therapy only if the patient is not able or willing to take his/her drug therapy that the practitioner has assessed to be appropriately indicated, effective, and safe for the patient38. Non-compliance: The patient is considered to be noncompliant with the drug therapy only if the patient is not able or willing to take his/her drug therapy that the practitioner has assessed to be appropriately indicated, effective, and safe for the patient38. Data collection techniques and instruments A structured questionnaire and standardized data abstraction format were developed after reviewing similar relevant studies2,18,39–41. The tools42 were designed to collect data on sociodemographic characteristics, clinical conditions, medical diagnoses, physical assessments, laboratory results, medications, comorbidities, previous medical history, and identified drug therapy problems. Data were obtained from patients, parents/caregivers, and electronic medical records. Three clinical pharmacists collected the data under the supervision of one MSc clinical pharmacy professional. The principal investigator and supervisors closely monitored the overall data collection process. Before the commencement of data collection, training was provided to data collectors and supervisors regarding the study objectives, ethical considerations, and proper use of the data collection tools. To assess clarity, completeness, and feasibility, the data collection instruments were pretested on 5% of the study participants (n = 8) at Kombolcha General Hospital, Dessie, Ethiopia, before the actual data collection. The pretest also included an assessment of internal consistency, for which Cronbach’s alpha was calculated, yielding a value of 0.79. Pharmaceutical interventions In addition to data collection, one MSc-trained clinical pharmacist provided pharmaceutical interventions through direct communication with the treating physicians to enhance treatment effectiveness, minimize adverse drug events, and optimize overall patient outcomes. After each DTP was identified, the clinical pharmacist communicated directly with the treating physician face‑to‑face during Multidisciplinary team rounds (MDT rounds) to propose one or more evidence‑based interventions for a single DTP, such as dose adjustment, drug substitution, addition or discontinuation of therapy, and patient counselling on medication adherence. Clinical pharmacists provided patient education/counselling on medication adherence not only for noncompliance-related DTPs but also for other relevant cases as needed. All interventions were documented using a standardized intervention form, and their acceptance by prescribers was recorded. Data analysis and management The data were coded and entered into Epi-Data version 4.6 software and then exported to SPSS version 27.0 for analysis. Descriptive statistics were carried out and presented with tabulation and graphical presentation. During analysis, frequencies and percentages were used to describe categorical variables while means and standard deviations were used to describe continuous variables. Binary logistic regression analysis was employed to identify factors associated with the outcome variable. Initially, bivariable logistic regression analysis was performed, and variables with a p-value < 0.25 were considered candidates for the multivariable logistic regression model. Before fitting the final model, multicollinearity among independent variables was assessed. The fitness and adequacy of the final model were evaluated using the Omnibus test, the Hosmer-Lemeshow goodness-of-fit test, and Nagelkerke’s pseudo R². In the multivariable logistic regression analysis, variables with a p-value < 0.05 at a 95% confidence interval were considered statistically significant. Ethical consideration Ethical clearance was obtained from the ethical institute review board (IRB) of the Asrat Weldeyes Health Sciences campus (AWHSC), Debre Birhan, with a reference number of Ref: SOP/197/2024. All the processes had been started after getting permission from DBHGTH. Privacy and confidentiality were ensured during the data collection process. Thus, the name and card number of the patient were not recorded in the data collection abstraction tool. Results Socio-demographic characteristics of the study participants Of 177 selected samples, a total of 163 patients were included in the study, of which 92 (56.44%) were males. Most of them, 67 (41.10%), were neonates, and the next infants, 33 (20. 24%), whereas school age covered the last 5 (3.07%) from all age groups admitted during the study. The mean weight of patients was 13.99 ± 10.27 kg. The mean (± SD) height of patients was 90 ± 32.02 cm. Of the total of 163 patients, 86 (52.76%) lived in Urban and the remaining patients lived in rural areas. In this study, traditional and herbal drug use was reported among 30 (18.40%) of the 163 patients (Table 1). Table 1Socio-demographic characteristics of pediatric patients at DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024 (n = 163).VariablesCategoriesFrequency (%)SexMale92 (56.44)Female71 (43.56)ResidenceRural77 (47.24)Urban86 (52.76)Age categoryNeonate (birth to 28 days)67 (41.10)Infant (29 days to ≤ 1 year)33 (20.24)Toddler (> 1 to ≤ 3 years)25 (15.34)Preschool (> 3 to ≤ 5 years)10 (6.13)School-age (> 5 to ≤ 10 years)5 (3.07)Adolescent (> 10 to < 18 years)23 (14.11)Body weight (kg)< 519 (11.66)5-9.952 (31.90)10-14.941 (25.15)15-19.916 (9.81)20-24.94 (2.45)≥ 2531 (19.02)History of traditional and herbal medicine use before hospital admissionYes30 (18.40)No133 (81.59) Socio-demographic characteristics of pediatric patients at DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024 (n = 163). Clinical characteristics of study participants Of the total of 163 patients, 45 (27.61%) had a past medical condition history, and 43 (26.38%) patients had a past medication history. The majority of patients, 79 (48.47%), stay in the hospital for less than five5 days. Of 163 patients included in the study, 92 (56.44%) had comorbidity. Most of the patients, 144 (88.34%), were new admissions to the pediatric ward of HGH (Table 2). Table 2Clinical characteristics of study participants admitted to the pediatric ward of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024 (n = 163).VariableCategoriesFrequency (%)Types of admissionNew144 (88.34)Transfer19 (11.65)Patient’s level of consciousnessConscious113 (69.33)Not Conscious50 (30.67)Severity of the diseaseHealthy looking82 (50.31)Acute sick looking51 (31.29)Chronic sick looking30 (18.40)Length of Hospital stay (day)≤ 5 days79 (48.47)6–10 days47 (28.83)> 10 day37 (22.70)Past medication historyYes43 (26.38)No120 (73.62)Past medical condition historyYes45 (27.61)No118 (72.39)Presence of comorbidityYes92 (56.44)No71 (43.56)Number of comorbidities0–1118 (72.39)> 145 (27.61)Polypharmacy (Current)No (< 5 drugs)125 (76.69)Yes (≥ 5 drugs)38 (23.31) Clinical characteristics of study participants admitted to the pediatric ward of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024 (n = 163). Admission diagnosis and comorbidities of the study participants The most common infectious diseases diagnosed during the study period were pneumonia, 66 (40.49%), followed by sepsis, 31 (19.02%) (Fig. 1). A total of 92 different comorbidities were diagnosed among 163 patients. The most common comorbidities were severe acute malnutrition (SAM) 35 (38.04%), followed by anemia 29 (31.52%) and rickets 15 (16.30%) (Fig. 2). Commonly diagnosed infectious diseases among patients admitted to the pediatric ward of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024 (n = 163). Footnote: SSTIS: Skin and soft tissue infections (Cellulitis, Deep bacterial folliculitis, Osteomyelitis), AGE: Acute gastroenteritis, SAM: Severe acute malnutrition. Others*: Acute viral hepatitis, Herpes simplex virus, Acute infectious endocarditis, Rheumatic Heart disease unspecified, Acute otitis media, urinary tract infection, and Acute tonsillitis. The comorbidities diagnosed among patients with infectious disease at the pediatric ward of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024 (n = 163). Footnote: SAM: Severe acute malnutrition. Others*: NYHA class-II chronic heart failure secondary to CRVHD, Retrovirus infection (RVI), Acute kidney injury (AKI), and Acute viral hepatitis. Frequently prescribed drug classes for infectious disease Antibiotics were the most frequently prescribed drug class, with a mean of 1.73 antibiotics per child, followed by analgesics, with a mean of 0.61 per child. Among all antibiotics and other medications, ceftriaxone was the most commonly prescribed, given to 101 (61.96%) of the children (Table 3). Table 3Total number of drugs prescribed among patients with infectious disease at the pediatric ward of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024.Drug classType of drugsFrequency (%)Antibiotics, 282 (1.73 per child)Ceftriaxone101 (61.96)Ampicillin50 (30.67)Gentamycin40 (24.54)Vancomycin25 (15.34)Metronidazole22 (13.50)Ceftazidime14 (8.59)Other antibiotics**30 (18.40)Analgesics. 100 (0.61 per child)Paracetamol43 (26.38)Morphine33 (20.24)Ibuprofen11 (6.75)Tramadol7 (4.29)Diclofenac6 (3.68)Corticosteroids, 17 (0.10 per child)Dexamethasone11 (6.75)Prednisolone6 (3.68) Respiratory drug 16 (9.81) Minerals and vitamins 15 (9.20)Others***68 (41.72)Footnote: Others**: Augmentin, azithromycin, cefepime, ciprofloxacin, cloxacillin.Others***: GI drug, CVS drug, antifungal drug, CNS drug. Total number of drugs prescribed among patients with infectious disease at the pediatric ward of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024. Footnote: Others**: Augmentin, azithromycin, cefepime, ciprofloxacin, cloxacillin. Others***: GI drug, CVS drug, antifungal drug, CNS drug. Types of DTPs in pediatric patients admitted to DBHGTH Of the total 163 participants, 70 (42.94%) had at least one DTP during their hospital stay. A total of 201 DTPs were identified among 70 patients. A total of 201 DTPs were obtained with a mean of 1.23 DTPs per patient, ranging from 1 to 3. DTPs were classified into seven categories along with their respective magnitude. Needs additional drug therapy, and patient noncompliance was the most predominantly encountered DTPs, accounting for 56 (27.86%) and 38 (18.9%), respectively, followed by unnecessary drug therapy, 32 (15.92%) of the total DTPs. Dosage too low 15 (7.46%) and adverse drug reaction 14 (6.96%) were the least DTPs identified. The causes of each DTP were explained in detail (Table 4). Table 4The common causes of DTPs identified among study participants in the pediatric ward of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024 (N = 201 different DTPs).DTP CategoryCommon causes of DTPs identifiedFrequency (%)Does the patient have DTPs during hospitalization(n = 163)Yes70 (42.94)No93 (57.05)Needs additional drug therapy 56 (27.86%) Untreated medical condition31 (55.36)Preventive/prophylactic drug therapy19 (33.93)Synergistic/ potentiating therapy6 (10.71)Patient Non-compliance 38 (18.90%) Patient does not understand instructions11 (28.95)The drug product is too expensive for the patient9 (23.68)The patient’s caregiver forgot to take medication7 (18.42)Drug product not available5 (13.16)Cannot swallow or self-administer appropriately4 (10.53)Patient prefers not to take the medication2 (5.26)Unnecessary drug therapy 32 (15.92%) Duplicate drug therapy14 (43.75)No need for drugs for that condition9 (28.12)No medical condition at the time6 (18.75)Others specify*3 (9.37)Ineffective drug therapy 29 (14.43%) Not effective for conditions13 (44.83)More effective alternatives are unavailable9 (31.03)Condition refractory to the drug8 (27.59)Dose too high 17 (8.46%) The dose is too high9 (52.94)The dosing frequency is too short5 (29.41)Duration too long4 (23.53)A drug interaction occurs, resulting in a toxic reaction to the drug product3 (17.65)The dose of the drug was administered too rapidly3 (17.65)Adjustment for renal impairment was not done2 (11.76)Dose too low 15 (7.46%) Frequency inappropriate10 (66.67)The duration of drug therapy is too short3 (20.00)Wrong dose (sub-therapeutic)2 (13.33)Adverse drug reaction 14 (6.96%) Allergic reaction6 (42.86)Undesired effect4 (28.57)Drug interaction2 14.29)Dosage administered or changed too rapidly2 (14.29) Total DTPs 201 (100%)Footnote: DTPs: Drug therapy problems, No: Number of. Out of 163 pediatric patients, 70 (42.94%) had ≥ 1 DTP (a total of 201 DTPs across these patients). The common causes of DTPs identified among study participants in the pediatric ward of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024 (N = 201 different DTPs). Needs additional drug therapy 56 (27.86%) Patient Non-compliance 38 (18.90%) Unnecessary drug therapy 32 (15.92%) Ineffective drug therapy 29 (14.43%) Dose too high 17 (8.46%) Dose too low 15 (7.46%) Adverse drug reaction 14 (6.96%) Footnote: DTPs: Drug therapy problems, No: Number of. Out of 163 pediatric patients, 70 (42.94%) had ≥ 1 DTP (a total of 201 DTPs across these patients). Types of pharmaceutical interventions and level of acceptability After identifying the DTPs, pharmaceutical interventions were undertaken through direct communication with the treating physicians to enhance treatment effectiveness, minimize adverse drug events, and optimize overall patient outcomes. A total of 251 interventions were provided. The most frequently implemented intervention was the initiation of a new medication (28.29%), followed by patient education/counselling and adherence support (24.30%), and dose adjustment (21.11%). Of the 251 interventions, 69.72% were fully accepted by the physicians. Overall, the interventions achieved an acceptance rate of 80.48% (Table 5). Table 5Clinical pharmacist intervention and acceptance level of interventions by physicians provided for patients diagnosed with infectious disease admitted to pediatric wards of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024.Type of pharmaceutical interventions by clinical pharmacistsFrequency (%)Adjust the dose of the drugs53 (21.11)Adjust the frequency of the drugs41 (16.33)Add a new drug71 (28.29)Discontinuation of the drug25 (9.96)Medication adherence and patient education/counselling delivered61 (24.30) Level of acceptability by physicians Intervention fully accepted175 (69.72Refused or rejected49 (19.52)Intervention accepted with modification (partially accepted)27 (10.76)Footnote: DBHGTH: Debre Birhan Hakim Gizaw Teaching Hospital. Of 201 total DTPs identified, clinical pharmacists proposed ≥ 1 intervention per DTP as needed. Patient education or counselling was provided not only for noncompliance-related DTPs but also for other relevant cases, resulting in adherence/counselling interventions exceeding the number of noncompliance DTPs. Clinical pharmacist intervention and acceptance level of interventions by physicians provided for patients diagnosed with infectious disease admitted to pediatric wards of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024. Footnote: DBHGTH: Debre Birhan Hakim Gizaw Teaching Hospital. Of 201 total DTPs identified, clinical pharmacists proposed ≥ 1 intervention per DTP as needed. Patient education or counselling was provided not only for noncompliance-related DTPs but also for other relevant cases, resulting in adherence/counselling interventions exceeding the number of noncompliance DTPs. Factors associated with DTPs Before conducting the multivariable logistic regression analysis, multicollinearity among independent variables was assessed using the variance inflation factor (VIF), and no significant multicollinearity was detected (all VIF values < 1.22). The fitness of the logistic regression model was evaluated using the Omnibus test and the Hosmer-Lemeshow goodness-of-fit test. The Omnibus test indicated that the model was statistically significant (χ² = 82.15, df = 11, p < 0.001). Furthermore, the Hosmer-Lemeshow goodness-of-fit test demonstrated adequate model fitness (p = 0.067). The model explained 53.1% of the variability in the outcome variable according to Nagelkerke’s pseudo R². In the bi-variable logistic regression analysis, patient residence, traditional herbal medicine use, length of hospital stays, polypharmacy, number of comorbidities, and patients’ body weight were factors associated with DTPs (p < 0.25). However, after controlling for the confounding variables in the multivariable binary logistic regression analysis (p-value < 0.05), patient residence, traditional herbal medicine use, length of hospital stays > 10 days, polypharmacy (≥ 5 drugs), and number of comorbidities (> 1) were found to be statistically significant variables associated with DTPs. Holding other covariates constant, patients living in rural areas were about 4.58 times more likely to experience DTPs compared with those residing in urban areas [AOR: 4.58, 95%CI: 1.94–10.81, p < 0.001]. The odds of experiencing DTPs were 4.66 times higher among patients who used herbal medicines compared with those who did not [AOR: 4.66, 95%CI: 1.28–16.97, p = 0.020]. Similarly, Patients with a prolonged duration of hospital stay (> 10 days) were about 6.18 times more likely to have DTPs as compared to their counterparts (≤ 5 days) [AOR: 6.18, 95%CI: 1.95–19.56, p = 0.002]. Furthermore, patients with polypharmacy (≥ 5 drugs) were about 3.91 times more likely to have DTPs compared to those with fewer medications (< 5 drugs) [AOR: 3.91, 95%CI: 1.33–11.48, p = 0.013]. Finally, the odds of DTPs were 4.27 times higher among patients with a greater number of comorbidities (> 1) compared with those having fewer comorbid conditions (≤ 1) [AOR: 4.27, 95% CI: 1.60–11.37, p = 0,004] (Table 6). Table 6Bi-variable and multivariable binary logistic regression analysis of factors associated with DTPs in the pediatric ward of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024 (n = 163).VariablesCategoryDTPCOR with 95% CIP-ValueAOR with 95% CIP-valueYesNoResidenceRural48294.82 (2.47, 9.4)< 0.0014.58 (1.94, 10.81) < 0.001 Urban22641Herbal medicine useNo46871Yes2467.56 (2.89, 19.82)< 0.0014.66 (1.28, 16.97) 0.020 Length of hospital stay≤ 5 days205916–10 days33242.83 (1.32, 6.07)0.0082.53 (0.95, 6.77)0.063> 10 days27107.96 (3.29, 19.30)< 0.0016.18 (1.95, 19.56) 0.002 Polypharmacy< 5 drugs40851≥ 5 drugs3087.97(3.35, 18.94)< 0.0013.91 (1.33, 11.48) 0.013 Number of Comorbidities≤ 137811> 133126.02 (2.8, 12.96)< 0.0014.27 (1.60, 11.37) 0.004 Body weight in (Kg)< 59100.74 (0.24, 2.33)0.6080.44 (0.10, 2.03)0.2905-9.923290.65 (0.27, 1.60)0.3510.42 (0.13, 1.44)0.16710-14.914270.43 (0.16, 1.11)0.0820.27 (0.07, 1.00)0.05315-19.95110.37 (0.11, 1.34)0.1300.36 (0.07, 1.84)0.21920-24.9220.82 (0.10, 6.62)0.8550.13 (0.01, 2.10)0.151≥ 2517141Footnote: 1: indicates reference, DTPs: drug therapy problems, COR: Crude odds ratio, AOR: Adjusted odds ratio, KG: Kilogram, CI: Confidence interval. Bi-variable and multivariable binary logistic regression analysis of factors associated with DTPs in the pediatric ward of DBHGTH, North Shewa, Ethiopia, from March 1 to August 31, 2024 (n = 163). Footnote: 1: indicates reference, DTPs: drug therapy problems, COR: Crude odds ratio, AOR: Adjusted odds ratio, KG: Kilogram, CI: Confidence interval. From this regression model, a VIF < 1.22 was found in the DTPs. The model fitting information was checked by the Omnibus test (at p < 0.05) (χ2 = 82.15, df = 11, P < 0.001) DTPs. The final model’s goodness-of-fit was checked by the Hosmer-Lemeshow test (at p-value > 0.05) at p-value = 0.067 in DTPs. Nagelkerke’s (pseudo R2) showed how much the independent variables explain the response variable (DTP) by 53.10% in the model. Discussion Inappropriate use of drugs during disease management may lead to DTPs. Identification of common types of DTPs and common drugs involved in DTPs is an important component of drug therapy and contributes to the reduction of drug-related morbidity and mortality. The majority of studies conducted in different countries showed a higher prevalence of drug-related problems and indicated different drugs and drug classes involved in DTPs43. In this study, the prevalence of DTPs was reported to be 42.94% [95% CI (35.52–50.90%)], which was in line with the results of studies done in Gondar, Ethiopia (40.20%)44, the United Kingdom45(39.40%), and Saudi Arabia45(45.20%). But the result of this study was higher than studies done in Zewditu hospital, Ethiopia41(31.57%), and Hong Kong46(21.00%). This difference might be attributed to variations in study populations, the types and severity of illnesses among patients, the hospital settings (tertiary vs. secondary care), prescribing practices, the availability and involvement of clinical pharmacists, and methodological differences such as study design, sample size, and criteria used to identify and classify DTPs. However, the prevalence of DTPs in this study was lower than that reported in other studies conducted in Ethiopia, such as Dessie (87.70%)47, Jimma (74.30%)2, and Tigray (77.60%)48. This difference may be partly attributed to the use of electronic-based prescribing and dispensing systems in our institution, which can help reduce certain types of medication-related problems. Specifically, such systems can reduce inappropriate dose or dosing frequency, drug-drug interactions, duplicate therapy, inappropriate drug selection (no indication or wrong drug choice), and prescription or transcription errors through clinical decision support functions such as dose checking, interaction alerts, and standardized order entry. According to this study, antibiotics were the most frequently prescribed class of drugs, with a mean of 1.73 antibiotics per child compared to other drug classes prescribed. This reflects the study’s inclusion of pediatric patients primarily diagnosed with infectious diseases, as well as the prophylactic antibiotic use in severe malnutrition cases due to their elevated infection risk from even single microorganisms. From the total of 282 antibiotics prescribed, 16 (5.67%) antibiotics had DTPs. This study documented both the types of DTPs and their underlying causes. The most common DTP identified was needs additional drug therapy 56 (27.86%), which was comparable with the study done in Ethiopia, such as Dessie (25.20%)47 and Gondar (28.89%)44, and four French-speaking countries (25.00%) and five pediatric clinics in Greece (28.00%)49. However, it was higher than the study done in Jimma, Ethiopia (11.24%). The observed differences between studies may be attributable to variations in study population characteristics, inclusion criteria, the methods used to identify and classify DTPs, the types of medications commonly prescribed, and the level of clinical pharmacy involvement across the different settings. In this study, noncompliance 38 (18.90%) was the second most common identified DTP, which is comparable to a study in Dessie (20.20%)47. However, a higher prevalence was reported in Jimma (28.65%)2. The observed differences between studies may be attributed to variations in study populations, patient age groups, underlying medical conditions, ward settings, the methods used to identify DTPs, caregiver involvement, literacy level, understanding of medication instructions, and the level of clinical pharmacy involvement in monitoring medication adherence. This collectively may be contributing for noncompliance. In this study, clinical pharmacists provided a total of 251 pharmaceutical interventions to address drug therapy problems. The most frequent intervention was adding a new drug (28.29%), followed by medication adherence support and patient education/counselling (24.30%). This pattern is consistent with previous studies conducted in Ethiopia, which reported that the most common clinical pharmacy interventions include initiation of appropriate drug therapy and patient counseling/adherence support50,51. Similarly, international studies have shown that pharmacist interventions frequently focus on optimizing therapy by starting indicated medications and improving patient adherence through counseling and education52. Regarding acceptability by physicians, the interventions achieved an acceptance rate of 80.48%. This level of acceptability is similar to other Ethiopian studies, such as those from Gondar (76.50%)44 and Jimma (79.49%)2. But this level of acceptance is lower than studies reported in India (86.60%)53 and France (98.00%)54. The discrepancies between studies may be influenced by differences in physician familiarity with clinical pharmacy services, perceived clinical relevance of recommendations, or institutional prescribing protocols. Regarding factors associated with DTPs, the present study demonstrated that patients living in rural areas were more likely to experience DTPs compared with those residing in urban areas. This finding was supported by other studies40. A possible justification might be that delayed presentation to healthcare facilities, lower health literacy, a higher likelihood of presenting with more advanced disease, and lower socioeconomic status55. In addition to this, these conditions often result in poor medication adherence and limited prior exposure to structured medication counselling56–58. In the present study, patients who used traditional and herbal medicines experienced DTPs compared with those who did not. This finding was supported by other studies59–61. A possible justification might be that many traditional and herbal medicines are classified as foods or supplements in certain countries, meaning they are not subject to the rigorous quality, safety, or efficacy testing required for prescription drugs. Patients often do not disclose herbal medicine use to healthcare providers, and providers may lack sufficient knowledge or resources to identify potential interactions or side effects. This gap can lead to misuse, overlapping toxicities, or missed counselling opportunities to avoid harmful combinations. Traditional and herbal medicines can interact with conventional drugs, altering their pharmacokinetics or pharmacodynamics, and some herbal medicines have inherent toxicities62. Case reports document severe effects like Stevens-Johnson syndrome or poisoning from misidentified or overdosed herbal products, which can complicate drug therapy63. However, the association observed in this study does not necessarily indicate a direct causal relationship between pre-admission herbal medicine use and all in-hospital DTPs. Rather, prior use of traditional/herbal medicines may contribute indirectly to the occurrence of DTPs through several mechanisms, including delayed healthcare-seeking behavior, incomplete or inaccurate medication histories, potential herb-drug interactions, organ toxicities affecting drug therapy, and increased disease severity at admission requiring complex medication regimens. Previous evidence has shown that concomitant use of herbal and conventional medicines may alter drug pharmacokinetics and pharmacodynamics, increase the risk of adverse drug reactions, and complicate clinical management, particularly among hospitalized patients receiving multiple medications. In addition, several reports have documented herb-related hepatotoxicity and other toxicities that may affect drug therapy outcomes and increase the likelihood of DTPs such as inappropriate drug selection, dosage problems, adverse drug reactions, and treatment ineffectiveness during hospitalization64–68. In this finding, prolonged hospital stay was positively associated with DTPs. This finding was supported by other studies2,69–71. This might be due to increased medication exposure and polypharmacy, frequent medication changes, greater severity and complexity of illness, and risk of hospital-acquired complications72. The current study revealed that polypharmacy (≥ 5 drugs) is positively associated with being more likely to have DTPs. This finding was supported by other studies conducted in Jimma2, Gondar44, Zewditu Hospital41, Hong Kong46, Saudi Arabia45, and London73. The possible reason may be that polypharmacy inherently increases the risk of drug-drug interactions due to the simultaneous presence of multiple pharmacologically active agents, which can potentiate adverse drug reactions or reduce therapeutic efficacy. Additionally, pediatric patients receiving multiple medications may face challenges related to medication administration and adherence, particularly due to caregiver understanding, dosing complexity, and scheduling difficulties, which can increase the risk of incorrect dosing or missed doses. The phenomenon of prescribing cascades, where additional drugs are prescribed to manage the side effects of other medications, further contributes to the complexity and risk of inappropriate medication use. Moreover, polypharmacy often reflects the burden of multiple comorbidities, which complicate therapeutic decision-making and increase vulnerability to adverse drug events. This complexity is compounded by factors such as the use of over-the-counter and complementary therapies that may not be fully disclosed or accounted for in clinical decision-making74. Finally, the present findings indicated that two or more comorbidities are positively associated with being more likely to have DTPs. This finding was supported by other studies2,25,44. The possible justification may be, firstly, that patients with multiple comorbid conditions often require complex therapeutic regimens involving numerous medications, which increases the risk of polypharmacy and drug-drug interactions. Secondly, these patients face challenges related to medication adherence and monitoring, as the complexity of their treatment plans can lead to confusion, non-compliance, and therapeutic duplications. Furthermore, the presence of comorbidities often exacerbates physiological vulnerabilities, such as impaired organ function, which affects drug metabolism and clearance, thereby increasing the potential for adverse drug reactions. Additionally, conflicting treatment objectives for coexisting diseases complicate the optimization of drug therapy, making it difficult to balance efficacy and safety75. Clinical implications of findings The moderate prevalence of DTPs among hospitalized pediatric patients indicates a substantial and clinically relevant burden that can adversely affect treatment outcomes. This highlights the need for routine identification, prevention, and timely resolution of DTPs in pediatric wards. The predominance of DTPs related to indication, particularly the need for additional drug therapy, suggests gaps in initial treatment assessment, including incomplete evaluation of comorbid conditions and disease severity. Clinicians should strengthen comprehensive medication review at admission and during follow-up, especially for infectious diseases. The high involvement of antibiotics in DTPs underscores the importance of antimicrobial stewardship programs, including appropriate drug selection, dosing, duration, and monitoring in pediatric patients. Strengthening adherence to treatment guidelines may help reduce unnecessary exposure and resistance. The significant association of DTPs with polypharmacy, prolonged hospital stay, multiple comorbidities, rural residence, and traditional herbal medicine use suggests that these high-risk groups require closer monitoring and targeted pharmaceutical care interventions. The effectiveness of interventions such as adding a new drug and patient/caregiver education emphasizes the critical role of clinical pharmacists as part of the multidisciplinary healthcare team. Integrating pharmacists into pediatric care can improve medication optimization, adherence, and patient safety. Strengths and limitations of the study The prospective follow-up design allowed for systematic and real-time data collection, allowing pharmacists to intervene promptly at the point of care, which enhances the clinical relevance and accuracy of identifying DTPs. However, this study had certain limitations. First, the unavailability of certain laboratory investigations limited the assessment of the severity and clinical consequences of some DTPs. Second, the relatively small sample size and the single-centre setting may restrict the generalizability of the findings to other healthcare facilities or populations. Third, this study did not assess the outcome of the intervention provided by Clinical pharmacist interventions. Finally, some variables relied on caregiver-reported information, which may be subject to recall bias. Conclusions The prevalence of DTPs in the pediatric ward of DBHGTH was moderate. This study found that 42.94% of participants experienced at least one DTP during their hospital stay. Needs for additional drug therapy were the top-ranking DTPs, followed by patient non-compliance and unnecessary drug therapy, respectively. In this study, the most common drug classes involved in DTPs were antibiotics, followed by analgesics. Addressing these issues through improved prescribing practices, enhanced clinical pharmacist involvement, and appropriate drug formulations can help reduce the occurrence of DTPs and improve health outcomes for pediatric patients. Recommendations Based on the findings of this study, the following recommendations are suggested: The health sector policymakers should continue to include clinical pharmacists in hospitals to involve and strengthen ward-based clinical pharmacy services. The health sector policymakers should continue to include clinical pharmacists in hospitals to involve and strengthen ward-based clinical pharmacy services. Clinical pharmacists should be actively involved in the identification and management of DTPs alongside other healthcare providers. Clinical pharmacists should be actively involved in the identification and management of DTPs alongside other healthcare providers. There should be active participation of clinical pharmacists during the provision of pharmaceutical care with other healthcare professionals. There should be active participation of clinical pharmacists during the provision of pharmaceutical care with other healthcare professionals. Clinical pharmacists should be identifying and resolving DTPs, and their involvement in pediatric care can significantly reduce medication errors and improve patient outcomes. Clinical pharmacists should be identifying and resolving DTPs, and their involvement in pediatric care can significantly reduce medication errors and improve patient outcomes. Researchers: large and comprehensive studies should be initiated in pediatrics to ensure the rational use of drugs by identifying existing DTPs. Researchers: large and comprehensive studies should be initiated in pediatrics to ensure the rational use of drugs by identifying existing DTPs. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements The authors would also like to thank Asrat Weldeyes Health Sciences campus, Debre Berhan University, AWHSC, and the Department of Pharmacy for their support and permission to carry out this research. We would like to thank the data collectors and the participants. Abbreviations Adjusted odds ratio Asrat Weldeyes Health Sciences campus Confidence interval Crude odds ratio Debre Birhan Hakim Gizaw Teaching Hospital Drug therapy problems Hakim Gizaw Hospital Severe acute malnutrition Statistical package for social science World Health Organization Author contributions SSA: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Software, Supervision, Validation, Visualization, writing – original draft, and Writing – review & editingAWT: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft, and Writing – review & editingYDB: Conceptualization, Data curation, Methodology, Project administration, Validation, Visualization, Writing – original draft, and Writing – review & editingMY: Conceptualization, Data curation, Formal analysis, Methodology, Software, Supervision, Validation, Visualization, Writing – original draft, and Writing – review & editingJWS: Conceptualization, Data curation, Formal analysis, Methodology, Software, Visualization, Writing – original draft, and Writing – review & editingKYG: Conceptualization, Data curation, Formal analysis, Methodology, Software, Supervision, Writing – original draft, and Writing – review & editingDAB: Conceptualization, Data curation, Formal analysis, Methodology, Software, Supervision, Writing – original draft, and Writing – review & editingSSA is responsible for the overall content and serves as the guarantor for this paper. All authors read, reviewed, and approved the final manuscript. Data availability Upon a reasonable request, the corresponding author will make the data sets used and/or analyzed during the current work available. Declarations Competing interests The authors declare no competing interests. Ethical approval Ethical clearance was obtained from the ethical institute review board (IRB) of AWHSC with a reference number of Ref: SOP179/2024. All the processes had been started after getting permission from DBHGTH. Privacy and confidentiality were ensured during the data collection process. Thus, the name and card number of the patient were not recorded in the data collection abstraction tool. The study protocol was performed in accordance with the Declaration of Helsinki. Consent for publication Written informed consent for publication was obtained from the patient’s parent(s)/legal guardian(s). Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement Upon a reasonable request, the corresponding author will make the data sets used and/or analyzed during the current work available.